Your browser doesn't support javascript.
Outcomes of SARS-CoV-2 infection in patients with pulmonary sarcoidosis: A multicenter retrospective research network study.
Hadi, Yousaf B; Lakhani, Dhairya A; Naqvi, Syeda F Z; Singh, Shailendra; Kupec, Justin T.
  • Hadi YB; Department of Internal Medicine, Department of Medicine, West Virginia University, Morgantown, WV, USA.
  • Lakhani DA; Department of Radiology, Department of Medicine, West Virginia University, Morgantown, WV, USA.
  • Naqvi SFZ; Section of Pulmonary and Critical Care Medicine, Department of Medicine, West Virginia University, Morgantown, WV, USA.
  • Singh S; Department of Internal Medicine, Department of Medicine, West Virginia University, Morgantown, WV, USA.
  • Kupec JT; Department of Internal Medicine, Department of Medicine, West Virginia University, Morgantown, WV, USA. Electronic address: jkupec@hsc.wvu.edu.
Respir Med ; 187: 106538, 2021 10.
Article in English | MEDLINE | ID: covidwho-1574473
ABSTRACT

BACKGROUND:

Analyses of COVID-19 infection outcomes in patients with preexisting pulmonary sarcoidosis are lacking and are limited to case reports or small case series with the largest study reporting outcomes of 37 patients. RESEARCH QUESTION Retrospective cohort study to assess clinical outcomes of 945 patients with pulmonary sarcoidosis, presenting with COVID 19, compared to a propensity matched cohort of patients without sarcoidosis. STUDY DESIGN AND

METHODS:

Analysis of a multi-center research network TriNETX was performed including patients more than 16 years of age diagnosed with COVID-19. Outcomes in COVID-19 positive patients with concurrent pulmonary sarcoidosis were compared with a propensity score matched cohort of patients without pulmonary sarcoidosis.

RESULTS:

A total of 278,271 patients with COVID-19 on the research network were identified, 954 patients (0.34 %) carried a diagnosis of pulmonary sarcoidosis. Mean age of patients with sarcoidosis was 56.3 ± 13.2 years, with female predominance (n = 619, 64.89 %). 49.69 % of the participants were African American (n = 474). Co-morbidities including hypertension, chronic lower respiratory diseases, diabetes mellitus, ischemic heart disease, nicotine dependence, and chronic kidney disease were more common in patients with pulmonary sarcoidosis when compared to the non-pulmonary sarcoidosis cohort (all p values < 0.01). In unmatched analysis, pulmonary sarcoidosis group had higher mortality, increased risk for hospitalization, intubation and need for renal replacement therapy. After propensity score matching, no difference in any of the outcome measures was observed.

INTERPRETATION:

Crude COVID-19 mortality and other clinical outcome measures are poor in pulmonary sarcoidosis cohort; however, propensity-matched analyses revealed no difference in outcomes, showing that higher mortality is driven by higher burden of comorbidities.
Subject(s)
Keywords

Full text: Available Collection: International databases Database: MEDLINE Main subject: Sarcoidosis, Pulmonary / COVID-19 Type of study: Cohort study / Observational study / Prognostic study Topics: Long Covid Limits: Adult / Aged / Female / Humans / Male / Middle aged Language: English Journal: Respir Med Year: 2021 Document Type: Article Affiliation country: J.rmed.2021.106538

Similar

MEDLINE

...
LILACS

LIS


Full text: Available Collection: International databases Database: MEDLINE Main subject: Sarcoidosis, Pulmonary / COVID-19 Type of study: Cohort study / Observational study / Prognostic study Topics: Long Covid Limits: Adult / Aged / Female / Humans / Male / Middle aged Language: English Journal: Respir Med Year: 2021 Document Type: Article Affiliation country: J.rmed.2021.106538